

AURUM PHARMACEUTICALS LIMITED

Directors' Report and

Unaudited Financial Statements

for the Year Ended 31 December 2022

Company Number: 02581060



AURUM PHARMACEUTICALS LIMITED

**Contents of the Financial Statements
for the year ended 31 December 2022**

	Page
Company Information	1
Directors' Report	2
Balance Sheet and Income Statement	3
Notes to the Financial Statements	4

AURUM PHARMACEUTICALS LIMITED

**Company Information
for the year ended 31 December 2022**

Directors:

B De Ultra De Sousa Barcelos
X P C Lasserre

Registered office:

Bampton Road
Harold Hill
Romford
Essex
RM3 8UG

Registered number:

02581060

AURUM PHARMACEUTICALS LIMITED

**Directors' Report
for the year ended 31 December 2022**

The directors present their report with the financial statements of the company for the year ended 31 December 2022.

Directors

The directors who have held office during the period from 1 January 2022 to the date of this report are as follows:

B De Ultra De Sousa Barcelos (appointed 17 January 2023)
B Deluard (resigned 13 September 2022)
X P C Lasserre (appointed 26 June 2023)
J B C Monin (appointed 1 November 2022, resigned 26 June 2023)
P E Parry (resigned 31 December 2022)
E Schmidt (resigned 31 December 2022)

Post balance sheet event


On 30 August 2023, a restructuring exercise of the UK subsidiaries of ultimate parent company Financière Verdi III took place, whereby direct ownership of Aurum Pharmaceutical Limited was transferred from Macarthys Laboratories Limited to its immediate parent entity Orphea Limited at par value for a total consideration of £100. There was no change in ultimate control to any entity.

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

On behalf of the board:

9/20/2023

.....
B De Ultra De Sousa Barcelos - Director

Date:
DocuSigned by:

50836B19F62F4D5...

AURUM PHARMACEUTICALS LIMITED
(REGISTERED NUMBER: 02581060)

Balance Sheet
31 December 2022

	Notes	£	2022 £	£	2021 £
Current assets					
Debtors	3	<u>103</u>		<u>103</u>	
Total assets less current liabilities			<u>103</u>		<u>103</u>
Capital and reserves					
Called up share capital	4		100		100
Capital redemption reserve			2		2
Retained earnings			<u>1</u>		<u>1</u>
Shareholders' funds			<u>103</u>		<u>103</u>

The company is entitled to exemption from audit under section 480 of the Companies Act 2006 for the year ended 31 December 2022.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2022 in accordance with section 476 of the Companies Act 2006.

The directors acknowledge:

- a) Ensuring the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- b) Preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to the financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board of Directors and were signed on its behalf by:

DocuSigned by:

Bruno Barcelos

50836B19F62F4D5

B De Ultra De Sousa Barcelos - Director

Date: 9/20/2023

Income Statement
For the year ended 31 December 2022

During the financial year and the preceding financial year, the company has not traded and has received no income and incurred no expenditure. Consequently, during those periods the company has made neither a surplus nor a deficit.

The notes form part of these financial statements

AURUM PHARMACEUTICALS LIMITED**Notes to the Financial Statements
for the year ended 31 December 2022****1. Statutory information**

Aurum Pharmaceuticals Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. Accounting policies**Basis of preparing the financial statements**

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

3. Debtors: amounts falling due within one year

	2022 £	2021 £
Amounts due from group undertakings	<u>103</u>	<u>103</u>

4. Called up share capital**Allotted, called up and fully paid**

	2022 £	2021 £
100 ordinary 'A' shares of £1 each	<u>100</u>	<u>100</u>

There is a single class of ordinary shares. There are no restrictions on dividends and the repayment of capital.

5. Controlling parties

Until 30 August 2023, the immediate parent company was Macarthys Pharmaceuticals Limited. On this date, the entire share capital was transferred to Macarthys Laboratories Limited's own immediate parent entity, Orphea Limited, who became the new immediate parent company of the Company.

The ultimate parent undertaking is Financière Verdi III, a company incorporated in France.

Financière Verdi III prepares group financial statements and copies can be obtained from:

Financière Verdi III
194, Bureaux de la Colline
92213 Saint-Cloud – FRANCE

6. Post balance sheet event

On 30 August 2023, a restructuring exercise of the UK subsidiaries of ultimate parent company Financière Verdi III took place, whereby direct ownership of Aurum Pharmaceutical Limited was transferred from Macarthys Laboratories Limited to its immediate parent entity Orphea Limited at par value for a total consideration of £100. There was no change in ultimate control to any entity.